Moneycontrol PRO
UPCOMING EVENT:Watch leaders discuss the biggest issue of our times at the Sustainability 100+ Summit. Register now!
you are here: HomeNewsBusiness

Orchid Pharma gets EIR from USFDA for its Alathur facility

The company has received EIR from the United States Food and Drug Administration (USFDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a filing to BSE.

September 21, 2017 / 03:40 PM IST
Praveg Communications (India) Ltd.

Praveg Communications (India) Ltd.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Orchid Pharma today said it has received establishment inspection report (EIR) from the US health regulator for its Alathur facility in Tamil Nadu.

The company has received EIR from the United States Food and Drug Administration (USFDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a filing to BSE.

The facility was inspected by the USFDA on May 2017, it added. Orchid Pharma stock shot up nearly 20 per cent to Rs 21.45 per scrip in the afternoon trade on BSE.
first published: Sep 21, 2017 03:33 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark